Targeting SLC Transporters: Small Molecules As Modulators and Therapeutic Opportunities

Overview

Journal Trends Biochem Sci

Specialty Biochemistry

Date 2023 Jun 24

PMID 37355450

Authors

Avner Schlessinger

Nicole Zatorski

Keino Hutchinson

Claire Colas

Affiliations

Soon will be listed here.

Abstract

Solute carrier (SLCs) transporters mediate the transport of a broad range of solutes across biological membranes. Dysregulation of SLCs has been associated with various pathologies, including metabolic and neurological disorders, as well as cancer and rare diseases. SLCs are therefore emerging as key targets for therapeutic intervention with several recently approved drugs targeting these proteins. Unlocking this large and complex group of proteins is essential to identifying unknown SLC targets and developing next-generation SLC therapeutics. Recent progress in experimental and computational techniques has significantly advanced SLC research, including drug discovery. Here, we review emerging topics in therapeutic discovery of SLCs, focusing on state-of-the-art approaches in structural, chemical, and computational biology, and discuss current challenges in transporter drug discovery.

Citing Articles

SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells.

Kim M, Hong W, Kang H, Kim J, Lee D, Cheong J Cell Death Dis. 2025; 16(1):161.

PMID: 40055335 PMC: 11889219. DOI: 10.1038/s41419-025-07476-5.

Unveiling the oncogenic role of SLC25A13: a multi-omics pan-cancer analysis reveals its impact on glioma progression.

Wu W, Liu S, Ren H, Rao Y, Nie J, Wei K Cancer Cell Int. 2025; 25(1):76.

PMID: 40033307 PMC: 11874833. DOI: 10.1186/s12935-025-03696-z.

Predicting substrates for orphan solute carrier proteins using multi-omics datasets.

Zhang Y, Newstead S, Sarkies P BMC Genomics. 2025; 26(1):130.

PMID: 39930358 PMC: 11812203. DOI: 10.1186/s12864-025-11330-5.

The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.

Du J, Shen M, Chen J, Yan H, Xu Z, Yang X Front Pharmacol. 2025; 15():1510080.

PMID: 39850557 PMC: 11754210. DOI: 10.3389/fphar.2024.1510080.

Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma.

Liao Y, Chen J, Yao H, Zheng T, Tu J, Chen W J Transl Med. 2025; 23(1):103.

PMID: 39844299 PMC: 11752724. DOI: 10.1186/s12967-025-06086-1.

References

Fenollar-Ferrer C, Stockner T, Schwarz T, Pal A, Gotovina J, Hofmaier T . Structure and regulatory interactions of the cytoplasmic terminal domains of serotonin transporter. Biochemistry. 2014; 53(33):5444-60. PMC: 4147951. DOI: 10.1021/bi500637f. View

Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T . The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997; 49(8):796-801. DOI: 10.1111/j.2042-7158.1997.tb06115.x. View

Tanda G, Hersey M, Hempel B, Xi Z, Newman A . Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder. Curr Opin Pharmacol. 2020; 56:13-21. PMC: 8247144. DOI: 10.1016/j.coph.2020.07.007. View

Yan R, Zhao X, Lei J, Zhou Q . Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature. 2019; 568(7750):127-130. DOI: 10.1038/s41586-019-1011-z. View

Meixner E, Goldmann U, Sedlyarov V, Scorzoni S, Rebsamen M, Girardi E . A substrate-based ontology for human solute carriers. Mol Syst Biol. 2020; 16(7):e9652. PMC: 7374931. DOI: 10.15252/msb.20209652. View

Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith D . Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Mol Pharm. 2017; 14(12):4685-4693. PMC: 5826771. DOI: 10.1021/acs.molpharmaceut.7b00775. View

Chavent M, Duncan A, Sansom M . Molecular dynamics simulations of membrane proteins and their interactions: from nanoscale to mesoscale. Curr Opin Struct Biol. 2016; 40:8-16. PMC: 5404110. DOI: 10.1016/j.sbi.2016.06.007. View

Iancu C, Bocci G, Ishtikhar M, Khamrai M, Oreb M, Oprea T . GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems. Sci Rep. 2022; 12(1):1429. PMC: 8791944. DOI: 10.1038/s41598-022-05383-9. View

Fog J, Khoshbouei H, Holy M, Owens W, Vaegter C, Sen N . Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron. 2006; 51(4):417-29. DOI: 10.1016/j.neuron.2006.06.028. View

10.

Hediger M, Romero M, Peng J, Rolfs A, Takanaga H, Bruford E . The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 2003; 447(5):465-8. DOI: 10.1007/s00424-003-1192-y. View

11.

Rosenbrock H, Desch M, Wunderlich G . Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023; 273(7):1557-1566. PMC: 10465677. DOI: 10.1007/s00406-023-01576-z. View

12.

Niello M, Gradisch R, Loland C, Stockner T, Sitte H . Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy. Trends Pharmacol Sci. 2020; 41(7):446-463. PMC: 7610661. DOI: 10.1016/j.tips.2020.04.006. View

13.

Schlessinger A, Bonomi M . Exploring the conformational diversity of proteins. Elife. 2022; 11. PMC: 9023052. DOI: 10.7554/eLife.78549. View

14.

Coleman J, Yang D, Zhao Z, Wen P, Yoshioka C, Tajkhorshid E . Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. Nature. 2019; 569(7754):141-145. PMC: 6750207. DOI: 10.1038/s41586-019-1135-1. View

15.

Andersen J, Kristensen A, Bang-Andersen B, Stromgaard K . Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009; (25):3677-92. DOI: 10.1039/b903035m. View

16.

Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Zidek A . Highly accurate protein structure prediction for the human proteome. Nature. 2021; 596(7873):590-596. PMC: 8387240. DOI: 10.1038/s41586-021-03828-1. View

17.

Chien H, Colas C, Finke K, Springer S, Stoner L, Zur A . Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018; 61(16):7358-7373. PMC: 6668346. DOI: 10.1021/acs.jmedchem.8b01007. View

18.

Harpole T, Delemotte L . Conformational landscapes of membrane proteins delineated by enhanced sampling molecular dynamics simulations. Biochim Biophys Acta Biomembr. 2017; 1860(4):909-926. DOI: 10.1016/j.bbamem.2017.10.033. View

19.

Kenakin T, Christopoulos A . Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013; 12(3):205-16. DOI: 10.1038/nrd3954. View

20.

Haferkamp S, Drexler K, Federlin M, Schlitt H, Berneburg M, Adamski J . Extracellular Citrate Fuels Cancer Cell Metabolism and Growth. Front Cell Dev Biol. 2021; 8:602476. PMC: 7793864. DOI: 10.3389/fcell.2020.602476. View